Merck (MSD) Clinical Trial Pipeline — 235 Active Studies

Phases, active trials: Phase 1: 36, Phase 2: 91, Phase 3: 104, Other: 4

Merck (known as MSD outside the US) operates the world's most commercially successful immuno-oncology franchise, built around Keytruda (pembrolizumab), the anti-PD-1 checkpoint inhibitor. Keytruda has over 1,600 clinical trials registered globally — more than any single drug in history. In addition to Keytruda combinations, Merck is advancing next-generation IO programs including LAG-3, TIGIT, and tumor-infiltrating lymphocyte (TIL) therapies. In oncology beyond IO, Welireg (belzutifan) for HIF-2α-driven cancers (VHL disease, RCC) represents a new mechanism. Their infectious disease pipeline includes RSV vaccines, HIV treatments, and next-generation HPV-related programs.

• Immuno-oncology (PD-1 combinations)
• Next-generation IO (LAG-3, TIGIT, TIL)
• Solid tumors across all major indications
• Infectious disease / vaccines
• Rare metabolic disease (VHL, HIF-2α)

• Keytruda (pembrolizumab) — PD-1 checkpoint, pan-tumor
• Welireg (belzutifan) — HIF-2α, RCC/VHL disease
• MK-2870 (sacituzumab tirumotecan) — TROP2 ADC
• Ladiratuzumab vedotin — LIV-1 ADC (breast/urothelial)
• MK-1308 (quavonlimab) — CTLA-4
• Islatravir — HIV NRTTI

Merck registers more new trials per month than any other industry sponsor. The Keytruda combination engine alone accounts for dozens of new trial registrations annually across tumor types. Competitive intelligence professionals covering any solid tumor must monitor Merck's pipeline.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Merck (MSD)'s registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Merck (MSD) may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.